BiP inhibitor BPR001-615 in colorectal adenocarcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study explores the effects of the experimental BiP inhibitor BPR001-615 on human colorectal cancer cells obtained from patients. The aim is to see if blocking BiP activity reduces cancer cell viability and growth in a dose-dependent manner. Eligible participants are adults with histologically confirmed colorectal adenocarcinoma who are scheduled for primary tumor resection at CHU de Nice. The study focuses on translational biology using tumor tissue from surgical procedures. No collaborators are listed beyond the lead sponsor at CHU de Nice.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 years or older.
* Histologically confirmed colorectal adenocarcinoma.
* Planned surgical resection of the primary colorectal tumor at Nice University Hospital.

Exclusion Criteria:

* Digestive tumor other than an adenocarcinoma, including a neuroendocrine tumor, lymphoma, gastrointestinal stromal tumor, or metastasis from another primary cancer.
* Intraoperative or pathological findings showing a diagnosis other than colorectal adenocarcinoma.

Where it's running

• CHU de Nice
  Nice, France Recruiting

Study contacts

• Principal investigator: Sebastien FREY, Dr — Centre Hospitalier Universitaire de Nice
• Study coordinator: Sebastien FREY, Dr
• Email: frey.s@chu-nice.fr
• Phone: + 33 4 92 03 60 00

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• VVD-133214 with Pembrolizumab in advanced colorectal cancer

  This study tests whether adding VVD-133214 to pembrolizumab helps people with advanced colorectal cancer better than pembrolizumab alone.

  Recruiting at 9 sites Phase 2 Vividion Therapeutics, Inc. · Tucson, Arizona and 121 other locations · NCT07811193

• Paclitaxel given inside the abdomen with systemic therapy for GI cancers with peritoneal spread

  This phase II study tests a combination of intraperitoneal and systemic chemotherapy (paclitaxel) in adults with digestive tract cancers that have spread to the peritoneum.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT07795749

• Breath test to help detect gastrointestinal cancers early

  A breath test that looks for signals in exhaled air to see if someone with gut cancer symptoms might have oesophageal, stomach, pancreatic, liver, or colorectal cancer and need urgent testing.

  Recruiting Imperial College London · Maidstone, Kent and 5 other locations · NCT07714538

• TLR9-based immunotherapy for peritoneal cancer with ascites

  This trial tests ACM-CpG injections into the abdomen to see if it’s safe and can help people with peritoneal metastases or malignant ascites from colorectal or appendiceal cancer.

  Recruiting Phase 1 Brown University · Providence, Rhode Island · NCT07658196

• Combining botensilimab and balstilimab after standard treatment for colorectal cancer

  This phase 2 trial tests whether giving botensilimab and balstilimab after standard therapy can clear detectable ctDNA in adults with stage II/III colorectal cancer.

  Recruiting at 2 sites Phase 2 National Cancer Institute (NCI) · New Orleans, Louisiana and 1 other locations · NCT07551596

• First-line trastuzumab-deruxtecan with capecitabine and bevacizumab for HER2-positive metastatic colorectal cancer

  This trial tests whether giving trastuzumab-deruxtecan together with capecitabine and bevacizumab as first treatment helps people with HER2-positive metastatic or unresectable colorectal cancer shrink tumors and respond better.

  Recruiting at 28 sites Phase 2 Gruppo Oncologico del Nord-Ovest · Lyon and 27 other locations · NCT07407465

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.